Aktis Oncology and Eli Lilly Announce $1.1 Billion Strategic Collaboration

May 21, 2024, 01:10 PM

Aktis Oncology announced on Tuesday a strategic collaboration with Eli Lilly to develop novel anticancer radiopharmaceuticals. The partnership includes milestone payments of up to $1.1 billion and royalties on sales. Aktis will receive an upfront payment of $60 million. This collaboration follows Eli Lilly's acquisition of radiopharma company Point Biopharma for $1.4 billion last year, highlighting Lilly's deepening investment in radiopharmaceuticals.